EXACT Therapeutics

Mindre end 1K følgere

EXTX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Investorkonsensus

EXACT Therapeutics operates in the medical technology sector. The company specializes in the development of medical devices. The product portfolio is broad and includes, for example, technical platforms for drug testing. In addition to the main business, related ancillary services and value-added products are also offered. The business is operated globally with the largest presence in the Nordic market. The company was previously known as Phoenix Solutions and is headquartered in Oslo.

Markedsværdi

-

Aktieomsætning

-

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse25.11.2025, 11.57

EXTX: EXACT Therapeutics to present company update

EXACT Therapeutics

Selskabsmeddelelse24.11.2025, 07.25

EXACT Therapeutics AS: New option program and receipt of share options by primary insiders

EXACT Therapeutics

Selskabsmeddelelse25.9.2025, 06.00

EXTX: EXACT Therapeutics first half 2025 interim results

EXACT Therapeutics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse18.9.2025, 06.00

EXTX: EXACT Therapeutics' Phase 2 trial to be presented at the 2025 AACR Special Conference

EXACT Therapeutics

Selskabsmeddelelse9.9.2025, 06.00

EXTX: EXACT Therapeutic's Acoustic Cluster Therapy to be presented at the Ninth International Cancer lmmunotherapy Conference

EXACT Therapeutics

Selskabsmeddelelse12.8.2025, 06.30

EXTX: EXACT Therapeutics to Present at the European Society for Medical Oncology (ESMO) Congress 2025

EXACT Therapeutics

Selskabsmeddelelse11.8.2025, 09.08

EXTX: Financial calendar

EXACT Therapeutics

Selskabsmeddelelse8.7.2025, 06.30

EXTX: EXACT Therapeutics announces grant of core patent in the U.S.

EXACT Therapeutics

Selskabsmeddelelse24.6.2025, 06.00

EXTX: EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

EXACT Therapeutics

Selskabsmeddelelse13.6.2025, 10.09

EXACT Therapeutics AS: Primary insider notification

EXACT Therapeutics

Selskabsmeddelelse13.6.2025, 10.05

EXTX: EXACT Therapeutics minutes from Annual General Meeting June 13, 2025

EXACT Therapeutics

Selskabsmeddelelse4.6.2025, 07.20

EXACT Therapeutics AS - Information regarding voting at the Annual General Meeting 2025

EXACT Therapeutics

Selskabsmeddelelse28.5.2025, 12.53

EXACT Therapeutics AS - Notice of Annual General Meeting 2025

EXACT Therapeutics

Selskabsmeddelelse20.5.2025, 06.30

EXTX: EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer

EXACT Therapeutics

Selskabsmeddelelse14.5.2025, 06.35

EXTX: EXACT Therapeutics announces grant of key patent covering non-invasive delivery of pharmaceuticals to the brain

EXACT Therapeutics

Selskabsmeddelelse7.5.2025, 08.47

EXTX: EXACT Therapeutics announces grant of key patent in Japan

EXACT Therapeutics

Selskabsmeddelelse9.4.2025, 19.17

EXACT Therapeutics - 2024 Annual Report

EXACT Therapeutics

Selskabsmeddelelse28.1.2025, 07.00

EXTX: EXACT Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice Model

EXACT Therapeutics

Selskabsmeddelelse7.1.2025, 10.58

EXTX: Financial calendar

EXACT Therapeutics

Selskabsmeddelelse24.12.2024, 11.52

EXACT Therapeutics AS: Share capital increase registered

EXACT Therapeutics

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.